Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

16.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
16.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
T Cell Types and Functions01:24

T Cell Types and Functions

2.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anaesthesia for infants and young children with achondroplasia.

BJA education·2025
Same author

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Enrichment of CD7<sup>+</sup>CXCR3<sup>+</sup> CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.

European journal of cancer (Oxford, England : 1990)·2024
Same author

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same journal

HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Mechanisms regulating T-cell infiltration and activity in solid tumors.

E Lanitis1, D Dangaj1, M Irving1

  • 1The Ludwig Branch for Cancer Research of the University of Lausanne, Epalinges.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 19, 2017
PubMed
Summary
This summary is machine-generated.

T-lymphocytes are crucial for cancer immunity, but tumors employ defenses to block their infiltration. This review explores T-cell regulation and immunotherapies to enhance anti-tumor responses.

Keywords:
T cellscancerimmunotherapytumor microenvironment

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.7K
A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes
07:29

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes

Published on: December 6, 2014

20.5K

Related Experiment Videos

Last Updated: Feb 20, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.7K
A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes
07:29

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes

Published on: December 6, 2014

20.5K

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • T-lymphocytes are vital for anti-cancer immunity, with their presence linked to better patient survival and immunotherapy response.
  • Tumors develop defense mechanisms to impede T-cell infiltration and function.
  • Factors like genetics, prior antigen exposure, and the microbiome influence T-cell responses to cancer and immunotherapy.

Purpose of the Study:

  • To review mechanisms regulating T-cell homing, infiltration, and activity within solid tumors.
  • To summarize current immunotherapies and combination strategies for overcoming tumor-induced immune suppression.

Main Methods:

  • Literature review of T-cell function in cancer immunity.
  • Analysis of tumor defense mechanisms against T-cells.
  • Summary of immunotherapeutic approaches and combinatorial strategies.

Main Results:

  • Tumors actively suppress T-cell infiltration and activity through various mechanisms.
  • Patient and tumor intrinsic factors significantly modulate T-cell repertoire and immunotherapy sensitivity.
  • Current immunotherapies aim to reinvigorate T-cells and overcome tumor-mediated suppression.

Conclusions:

  • Understanding T-cell regulation in the tumor microenvironment is key to improving cancer immunotherapy.
  • Combination strategies hold promise for enhancing T-cell-mediated tumor control and patient outcomes.
  • Targeting tumor defenses and modulating host factors can optimize immunotherapy efficacy.